Background of the study rnPatients with multiple myeloma are being seen in increasing frequency in different hospitals of therncountry. However, local data regarding the demographic, clinical characteristics, treatmentrnoutcome, and risk stratification of patients is lacking. This study was designed to fill this existing rngap in our setup. This will aid in the revision of treatment regimens based on a local data on thernefficacy of treatment regimens and risk stratification of patients with a newly diagnosed Myeloma rnPatients and MethodsrnA single centered Hospital-based retrospective Cohort study was conducted from January 2015 to rnDecember 2019. A total of 80 patients with newly diagnosed MM who received non Proteasomerninhibitor based therapy at TASH, Addis Ababa, Ethiopia were analyzed in the study. rnResults rnIn this cohort 63.8% of the patients were males (M:F ratio 1.76:1) and the median age at diagnosis rnwas 52 years. The commonest complications identified were Anemia (56.3%) and pathologicrnfracture (55%). The commonest comorbid conditions were; systemic hypertension (24%), CKDrn(6.3%), and Diabetes (5%). The median PFS and OS of patients were found to be 17.5 and 20rnmonths respectively. This study also identified factors like advanced DS stage, presence ofrnPlasmacytoma, renal dysfunction, elevated serum LDH, high level of serum protein, andrnMonoclonal M protein to be significant contributors in negatively affecting OS and PFS of patients. rnConclusionrnIn our setup, Myeloma is more common in the male population group and our patients are younger rnthan the western population. Myeloma treatment regimens like CP and CPT are found to performrnless in our patients than in patients elsewhere. This is likely due to the advanced stage atrnpresentation. In resource-limited areas, different clinical and laboratory parameters can still servernas of patient survival.